Roha ramp-up softness and legacy project overhang dominate Q1 FY27 call

Ion Exchange (India) Limited — Q1 FY27 Earnings Conference Call (for quarter ended June 30, 2026)

Call date: Aug 10, 2026 (transcript submitted Aug 17, 2026)

1. Overall Tone of Management: Neutral (slightly optimistic, but constrained by ongoing headwinds)

• Management is confident on long-term growth (Roha ramp-up, membranes expansion, services scaling, “emerging solutions” like PFAS/resource recovery/green hydrogen).
• However, they repeatedly emphasize near-term profitability pressure:
• Treatment solutions EBIT loss: “profitability continues to be impacted by certain legacy projects”
• Roha stabilization: “softer than what we expected” and “by the end of the second quarter… better position”
• Legacy/UP funding uncertainty: “far too premature to say that the project will be closed in this financial year”

2. Key Themes from Management Commentary

• Segment reclassification for transparency: Engineering split into Treatment Solutions / Industrial Products / Lifecycle Services to better reflect the pivot from EPC/project-heavy reporting to products + recurring services.
• Roha plant as the core growth engine:
• “5x capacity expansion” narrative (global resin volume share aspiration; capacity debottlenecking across Roha + Ankleshwar).
• Focus on stabilization, certifications, and overseas offtake (WQA/WQA-like certification referenced; North America/WQA discussed in Q&A).
• Membranes and standard plants scaling:
• Goa membrane manufacturing expansion; UF/MBR range; partnership with MANN+HUMMEL.
• Industrial products growth expected from UF capacity + standard plants + overseas presence.
• Lifecycle Services as recurring revenue / asset-light direction:
• O&M/BOOT/BOO/rental/digital solutions; example: 20-year O&M concession in Oman.
• Profitability remains the key constraint:
• Treatment solutions: EBIT loss due to legacy projects.
• Specialty chemicals: EBIT down due to Roha costs + geopolitical factors; expectation that margins improve as utilization improves.
• Consumer products: improving losses; target break-even in FY27.
• Macro/geopolitical impacts:
• Continued uncertainty affecting invoicing, input costs, and utilization ramp-up.

3. Q&A Analysis

Theme A: Reclassification rationale & segment economics

• Core questions
• Why reclassify? Any corporate action? What does it change for investors?
• Clarify Roha “5x” capacity claim and how it maps to revenue expectations.
• Management response
• Reclassification is not a corporate action: “objective is only to offer more transparency… share investments… growth… not talked about.”
• Engineering was previously “construed as projects business” though it had growing products/services.
• Roha “5x” explained as global resin capacity expansion via Roha + debottlenecking Ankleshwar; Phase I ~2x, Phase II ~5x.
• Notable / evasive / partial
• When asked to quantify margin/revenue impact by geography or by Roha vs prior revenue numbers, management avoided specifics:
  • “don’t talk about specific margins for particular geography”
  • For resin revenue mapping, they did not confirm a clean INR-to-INR uplift (kept it qualitative; “we will come back / offline”).

Theme B: Roha plant utilization, ramp-up, and margin impact

• Core questions
• Current utilization vs prior guidance (25% utilization in first full year / FY27).
• How Roha affects chemical margins (gross/EBIT), and timeline to claw back.
• Pharma resin 6x expansion status and capex/asset-turn expectations.
• Management response
• Utilization: still holding guidance but admitted softness:
  • “It has been softer than what we expected… not throwing in the towel… better position by end of Q2.”
• Margin drivers: Roha impact quantified at segment level:
  • “impact… approximately 6% at the segment level” (and additional FX gain absence + input cost lag).
• Pharma resins: in process; “on course to get that done in the next 12 months”; capex “manageable” but no detailed numbers.
• Notable / evasive / partial
• Multiple requests for quantification (utilization %, capex, revenue contribution, margin profile) were met with non-committal answers:
  • “we typically have not given a breakup”
  • “not in a position to give you a breakup”
  • “we would not be in a position to give a quantification” (e.g., WQA contribution)

Theme C: Treatment solutions profitability & legacy project overhang

• Core questions
• Why profitability has been weak for years; when will it normalize?
• Is “worst behind us”?
• UP legacy contract status and how much remains; receivables exposure.
• Management response
• Legacy headwinds acknowledged as ongoing:
  • “significant part… still left to be done”
  • “far too premature” to close in FY27.
• Strategy to improve mix:
  • “be selective… walk away from difficult projects”
  • shift toward advanced/emerging solutions (resource recovery, brine valorization, PFAS destruction, hydrogen, lithium extraction).
• UP unexecuted portion disclosed:
  • “UP unexecuted portion is around 11% of the order backlog as of June”
• Notable / unusually strong
• They corrected a prior misunderstanding:
  • “We have never said that the UP contract will be fully over in this financial year”
• They also clarified lifecycle services profitability reporting is not one-to-one:
  • “significant share of profitability sits within our products and chemicals segments”

Theme D: Overseas growth & certifications (Portugal/Europe, North America/WQA)

• Core questions
• Portugal/Spain acquisition progress and margin profile.
• WQA certification contribution to revenue and incremental growth in Americas.
• Management response
• Portugal: integration completed; “good potential of growth”; upside in Iberian + North Africa; margins “similar or better than India” but no quantification.
• North America/WQA: certification is “a must”; expects Roha capacity utilization to come from overseas, especially North America; no current-quarter revenue quantification.
• Notable / evasive
• Repeated refusal to quantify incremental margin/revenue by geography/certification:
  • “would not be in a position to give a quantification”

Theme E: Lifecycle services cash conversion / working capital

• Core questions
• Will lifecycle services improve working capital velocity vs EPC?
• Any structural free cash flow improvement?
• Management response
• Qualitative confirmation:
  • “step… towards having a less capital-intensive growth plan”
• Concrete example: 20-year O&M concession (Oman) for repeatable revenue.
• No direct cash conversion metrics provided.

4. Guidance / Outlook

Explicit guidance (quantitative)

• Roha utilization / ramp-up
• In Q&A: still targeting ramp consistent with prior plan; WQA/capacity utilization expected to support overseas demand.
• Earlier Roha guidance referenced: 25% utilization (first full year / next financial year), but in this call management said utilization is softer than expected and will reassess by end of Q2.
• Consumer products profitability
• “plan is to see if we can break even in this financial year”
• Order book / pipeline (visibility)
• Order book: INR 2,473 crores as of June 2026 (excluding Hyundai contract won post-quarter).
• Bid pipeline: INR 9,777 crores
• UP legacy
• “UP unexecuted portion is around 11% of the order backlog as of June”

Implicit signals (qualitative)

• Treatment solutions: profitability improvement is not immediate; legacy projects still “grind it out.”
• Specialty chemicals: margin pressure tied to Roha costs and input costs; expects improvement as utilization improves.
• Industrial products: improving margins already in Q1; growth supported by UF membrane capacity and standard plants + overseas presence.
• Americas growth: WQA is a gating requirement; Roha volume expected to be used overseas.

5. Standout Statements (direct / high-signal)

• Reclassification intent
• “objective is only to offer more transparency… share the investments… growth… not talked about.”
• Roha utilization uncertainty
• “It has been softer than what we expected. But at this point in time, we are not throwing in the towel.”
• Legacy closure timing
• “far too premature to say that the project will be closed in this financial year”
• UP remaining
• “UP unexecuted portion is around 11% of the order backlog as of June.”
• Treatment solutions profitability strategy
• “be selective and… walking away from difficult projects”
• Consumer products target
• “first target… break even in this financial year”
• Lifecycle services reporting caveat
• “significant share of profitability sits within our products and chemicals segments… not one-to-one.”

6. Red Flags / Positive Signals

Red flags
– Guidance slippage / softness admitted: Roha utilization “softer than expected” with reassessment only by end of Q2.
– Legacy overhang persists: management corrected earlier assumptions and said closure in FY27 is not assured.
– Frequent non-quantification: repeated refusal to quantify margins/revenue contribution by geography (Portugal, WQA, Roha overseas mix).
– EBITDA deterioration vs revenue growth:
– Q1 FY27: operating income +20% YoY, but EBITDA down 49% YoY (margin compression).

Positive signals
– Order book and pipeline strength: INR 2,473 cr order book; INR 9,777 cr bid pipeline.
– Industrial products momentum: EBIT margin improved to 11.89% (from <6% YoY) supported by membranes/UF and standard plants.
– Lifecycle services growth: revenue +28% YoY; EBIT +22% YoY.
– Consumer products improving losses: loss reduced vs prior year; break-even target stated.

7. Historical Comparison & Consistency Analysis (vs prior 3 calls)

a. Change in Tone Over Time

• Q2 FY26 (Nov 2025): margins pressured but management framed as operational normalization; Roha commissioning progressing; more confidence in ramp.
• Q3 FY26 (Feb 2026): still headwinds from Roha costs/depreciation and UP funding; but expectation of gradual scale-up.
• Q4 & FY26 (May 2026): Roha commissioned; WQA certification obtained; still margin pressure from Roha and input costs; legacy execution continuing.
• Current Q1 FY27 (Aug 2026): tone is more cautious on near-term profitability:
• explicit admission: Roha utilization “softer than expected”
• legacy closure pushed out: “far too premature”
• Classification shift: More cautious than earlier calls, especially on timing of normalization.

b. Tracking Past Commitments vs Outcomes

• Roha utilization ramp
• Past statement (Q2 FY26 / Nov 2025): “expect… 25% capacity utilization… in the first 12 months” and ramp to full utilization over 3–4 years.
• Current (Q1 FY27): still holding guidance, but “softer than what we expected” and will update by end of Q2.
• Flag: ⏳ Delayed / under pressure on ramp pace (no explicit % miss given, but softness acknowledged).
• UP legacy closure timing
• Past (Q4 FY26 call, May 2026): management indicated closure expected by end of calendar year (as referenced by analyst in current call).
• Current correction: “We have never said that the UP contract will be fully over in this financial year” and funds-flow dependency; unexecuted portion still ~11%.
• Flag: ❌ Missed / reframed (timing pushed; earlier expectation not met).
• Treatment solutions profitability normalization
• Past (multiple calls): expectation that legacy pain would taper as projects complete; engineering margins should improve in H2.
• Current: treatment solutions still EBIT loss; “grind it out”; improvement depends on mix and new profitable contracts.
• Flag: ⏳ Delayed (no clear inflection yet).

c. Narrative Shifts

• From “engineering/EPC” to “solutions/products/services” is now formalized via reclassification.
• Legacy explanation becomes more explicit and prolonged:
• earlier: “timing issue / expected to taper”
• now: “far too premature” and “still left to be done”
• PFAS/emerging solutions narrative is stronger now (PFAS destruction/absorption emphasized in Q&A), aligning with the “advanced solutions” pivot.

d. Consistency & Credibility Signals

• Credibility: Medium
• Strength: management consistently attributes margin pressure to identifiable drivers (Roha costs, legacy projects, input cost lag, FX gains absence).
• Weakness: repeated timing deferrals (UP/legacy) and lack of quantification for key drivers (utilization, overseas margin uplift, WQA revenue contribution).
• They did correct a misunderstanding about UP closure—this improves credibility, but the underlying delay remains.

e. Evolution of Key Themes

• Demand / order intake: improving/healthy (order book and bid pipeline emphasized consistently).
• Margins: deteriorated in Q1 FY27 (EBITDA margin 4.54%) vs earlier periods where margins were higher; improvement expected later but not yet visible.
• Expansion: Roha + membranes + standard plants remain central; pharma resins expansion timeline reiterated.
• Legacy risk: persists as the dominant drag on treatment solutions profitability.

f. Additional Insights (cross-period intelligence)

• The reclassification is not just reporting—it’s risk management of narrative:
• By splitting engineering into treatment solutions/industrial products/lifecycle services, management can show industrial products margin improvement while treatment solutions remains under legacy drag.
• Overseas growth is increasingly tied to certifications and Roha utilization, but management avoids quantifying the revenue/margin lift—suggesting uncertainty in timing/impact.